SEC Filings

Form 10-K
ZOMEDICA PHARMACEUTICALS CORP. filed this Form 10-K on 02/26/2019
Document Outline
Entire Document (3748.4 KB)
Subdocument 1 - 10-K - FORM 10-K
Page 1 - UNITED STATES
Page 2 - Note. If a determination as to whether a particular person or entity is an affiliate cannot be made
Page 3 - PART I
Page 4 - Development of Companion Animal Diagnostics
Page 5 - Unmet Medical Needs
Page 6 - Product Pipeline
Page 7 - Diagnostics
Page 8 - Therapeutics
Page 9 - N/A
Page 10 - Research and Development
Page 11 - Intellectual Property
Page 12 - General
Page 13 - Other Regulatory Considerations
Page 14 - Legal Proceedings
Page 15 - We will need to raise additional capital to achieve our goals.
Page 16 - The audit opinion on our financial statements contains a going concern modification.
Page 17 - The companion animal care industry is subject to rapidly changing technology, which could make our p
Page 18 - We face competition from the validated human drugs from which our drug candidates are developed whic
Page 19 - Our ability to develop, manufacture and commercialize our drug product candidates is dependent on ou
Page 20 - Development of product candidates for use in companion animal health is an inherently expensive, tim
Page 21 - Under the terms of our partnership arrangements, we are required to make significant milestone and o
Page 22 - We will rely on third parties to conduct certain portions of our development activities. If these th
Page 23 - Even if our product candidates obtain regulatory approval, they may never achieve market acceptance
Page 24 - Pharmaceuticals for companion animals, like human pharmaceuticals, are subject to unanticipated post
Page 25 - If we fail to attract and keep senior management and key scientific personnel, we may be unable to s
Page 26 - We may not be able to obtain or maintain sufficient insurance on commercially reasonable terms or wi
Page 27 - Even if we receive regulatory approval for a product candidate, we will be subject to ongoing FDA-CV
Page 28 - Legislative or regulatory reforms with respect to veterinary pharmaceuticals or health care solution
Page 29 - Some of our products may or may not be covered by a patent. Further if an application is filed, it i
Page 30 - Our diagnostic technologies depend on certain technologies that are licensed to us. We do not contro
Page 31 - If the Internal Revenue Service determines that we are not a PFIC and you previously paid taxes purs
Page 32 - Our management owns a significant percentage of our common shares and will be able to exert signific
Page 33 - We will incur significant costs as a result of operating as a U.S. public company, and our managemen
Page 34 - Future sales of our common shares by our shareholders or the perception that these sales may occur c
Page 35 - PART II
Page 36 - MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
Page 37 - Revenue
Page 38 - JOBS Act
Page 39 - Loss Per Share
Page 40 - Cash Flows
Page 41 - Operating Activities
Page 42 - Off Balance Sheet Arrangements
Page 43 - Recently adopted accounting pronouncements
Page 44 - N/A
Page 45 - PART III
Page 46 - Non-Management Directors
Page 47 - Board Composition
Page 48 - Board Leadership Structure and Role in Risk Oversight
Page 49 - Employment and Consulting Agreements
Page 50 - Outstanding Equity Awards at Fiscal Year End
Page 51 - Stock Option Plans
Page 52 - Director Compensation
Page 53 - Equidebt Working Capital Facility
Page 54 - PART IV
Page 55 - N/A
Page 56 - N/A
Page 57 - SIGNATURES
Page 58 - Zomedica Pharmaceuticals Corp.
Page 59 - Independent Auditors' Report
Page 60 - Zomedica Pharmaceuticals Corp.
Page 61 - Zomedica Pharmaceuticals Corp.
Page 62 - Zomedica Pharmaceuticals Corp.
Page 63 - Zomedica Pharmaceuticals Corp.
Page 64 - Zomedica Pharmaceuticals Corp.
Page 65 - Zomedica Pharmaceuticals Corp.
Page 66 - Zomedica Pharmaceuticals Corp.
Page 67 - Zomedica Pharmaceuticals Corp.
Page 68 - Zomedica Pharmaceuticals Corp.
Page 69 - Zomedica Pharmaceuticals Corp.
Page 70 - Zomedica Pharmaceuticals Corp.
Page 71 - Zomedica Pharmaceuticals Corp.
Page 72 - Zomedica Pharmaceuticals Corp.
Page 73 - Zomedica Pharmaceuticals Corp.
Page 74 - Zomedica Pharmaceuticals Corp.
Page 75 - Zomedica Pharmaceuticals Corp.
Page 76 - Zomedica Pharmaceuticals Corp.
Page 77 - Zomedica Pharmaceuticals Corp.
Page 78 - Zomedica Pharmaceuticals Corp.
Page 79 - Zomedica Pharmaceuticals Corp.
Page 80 - Zomedica Pharmaceuticals Corp.
Page 81 - Zomedica Pharmaceuticals Corp.
Subdocument 2 - EX-10.27 - EXHIBIT 10.27
Page 1 - Exhibit 10.27
Page 2 - TABLE OF CONTENTS
Page 3 - TABLE OF CONTENTS
Page 4 - TABLE OF CONTENTS
Page 5 - TABLE OF CONTENTS
Page 6 - TABLE OF CONTENTS
Page 7 - dEVELOPMENT and supply AGREEMENT
Page 8 - N/A
Page 9 - N/A
Page 10 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 11 - N/A
Page 12 - N/A
Page 13 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 14 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 15 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 16 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 17 - 2. Governance
Page 18 - Project Managers. Each Party will appoint and maintain a project manager for each SOW during the ter
Page 19 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 20 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 21 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 22 - 5. Commercial License
Page 23 - No Implied Licenses; Retained Rights. Except as explicitly set forth in this Agreement, neither Part
Page 24 - Exclusivity.
Page 25 - Ex-U.S. Distribution. At least 180 days prior to distributing or selling, or engaging or licensing a
Page 26 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 27 - Initial Payment Failure Event ), then this Agreement will immediately terminate and be of no further
Page 28 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 29 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 30 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 31 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 32 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 33 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 34 - 8. Support
Page 35 - Joint Intellectual Property.
Page 36 - Qorvo Development License. During the Term, and subject to the terms of this Agreement, Zomedica her
Page 37 - Non-Disclosure and Non-Use. The Parties agree that it is imperative for each of them that Confidenti
Page 38 - Reproduction. The Recipient will not copy or reproduce the Confidential Information provided or made
Page 39 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 40 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 41 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 42 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 43 - Limitation of Liability. NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTA
Page 44 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 45 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 46 - Survival. All rights and obligations of the Parties that, by their nature must survive the expiratio
Page 47 - Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations under t
Page 48 - Governing Law; Jurisdiction; Venue. This Agreement and the performance hereunder will be governed by
Page 49 - Remedies. All remedies available to a Party hereunder are cumulative, and may, to the extent permitt
Page 50 - Interpretation. The Parties acknowledge and agree that: (a) each Party and its counsel reviewed and
Page 51 - N/A
Page 52 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 53 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 54 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 55 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 56 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 57 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 58 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 59 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 60 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 61 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Subdocument 3 - EX-10.28 - EXHIBIT 10.28
Page 1 - Exhibit 10.28
Page 2 - ARTICLE 3
Page 3 - N/A
Subdocument 4 - EX-21.1 - EXHIBIT 21.1
Page 1 - N/A
Subdocument 5 - EX-23.1 - EXHIBIT 23.1
Page 1 - N/A
Subdocument 6 - EX-31.1 - EXHIBIT 31.1
Page 1 - N/A
Subdocument 7 - EX-31.2 - EXHIBIT 31.2
Page 1 - N/A
Subdocument 8 - EX-32.1 - EXHIBIT 32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE FILE (What's this?)
XBRL Item - EX-101.SCH - XBRL SCHEMA FILE (What's this?)
XBRL Item - EX-101.CAL - XBRL CALCULATION FILE (What's this?)
XBRL Item - EX-101.DEF - XBRL DEFINITION FILE (What's this?)
XBRL Item - EX-101.LAB - XBRL LABEL FILE (What's this?)
XBRL Item - EX-101.PRE - XBRL PRESENTATION FILE (What's this?)
XBRL Viewer